YieldMax MRNA Option Income Strategy ETF (NYSEARCA:MRNY) Sees Significant Decrease in Short Interest

YieldMax MRNA Option Income Strategy ETF (NYSEARCA:MRNY) was the target of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 67,120 shares, a decline of 56.7% from the July 30th total of 154,895 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily trading volume, of 111,339 shares, the short-interest ratio is presently 0.6 days.

YieldMax MRNA Option Income Strategy ETF Stock Down 2.3%

YieldMax MRNA Option Income Strategy ETF stock traded down $0.77 during mid-day trading on Friday, reaching $32.62. 194,622 shares of the stock traded hands, compared to its average volume of 238,141. The business’s 50-day moving average is $19.81 and its 200-day moving average is $18.44. YieldMax MRNA Option Income Strategy ETF has a 12-month low of $13.60 and a 12-month high of $42.39.

YieldMax MRNA Option Income Strategy ETF Company Profile

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an exchange-traded fund that mostly invests in health care equity. The fund seeks to provide current income and capped gains on the Moderna stock (MRNA) through a synthetic covered call strategy, collateralized by cash and US Treasurys. The actively managed fund uses both standardized exchange-traded and FLEX options. MRNY was launched on Oct 23, 2023 and is issued by YieldMax.